title: Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer.
abstract: The purpose of this multicenter prospective and descriptive study was to determine late toxicities and outcomes among patients with non-metastatic breast cancer receiving concurrent bevacizumab (BV) and radiation therapy (RT) in the clinical trials. Early and late toxicities were assessed and evaluation was available for 63 patients (pts) at 12 months. Acute radiation dermatitis was observed in 48 (76%): grade 1 for 27, grade 2 for 17 and grade 3 for 4 pts. Grade 2 acute oesophagitis was observed in one patient (2%). Little toxicity was described 1 year after the completion of RT: 7 pts (12%): grade 1-2 pain, 3 (5%) presented grade 1 fibrosis, and 2 pts (4%) - telangiectasia. One patient (2%) experienced grade 1 dyspnoea. Five grade 1-2 lymphoedema occurred. Only one patient experienced a LEVF value less than 50% one year after the end of RT. In conclusion, the concurrent BV with locoregional RT provides acceptable toxicities.
authors.affiliation: Institut Curie, Hospital, Radiotherapy Department, 75005 Paris, France.
authors.forename: Victor
authors.initials: V
authors.lastname: Pernin
authors.affiliation: Institut Curie, Hospital, Biostatistic Department, 75005 Paris, France.
authors.forename: Lisa
authors.initials: L
authors.lastname: Belin
authors.affiliation: Institut Curie, Hospital, Oncology Department, 75005 Paris, France.
authors.forename: Paul
authors.initials: P
authors.lastname: Cottu
authors.affiliation: CHU Jean Minjoz, Radiotherapy Department, 25030 Besançon, France.
authors.forename: Patrick
authors.initials: P
authors.lastname: Bontemps
authors.affiliation: Institut régional du Cancer de Montpellier, Radiotherapy Department, 34298 Montpellier, France.
authors.forename: Claire
authors.initials: C
authors.lastname: Lemanski
authors.affiliation: Institut Curie, Hospital, Radiotherapy Department, 92210 Saint Cloud, France.
authors.forename: Brigitte
authors.initials: B
authors.lastname: De La Lande
authors.affiliation: Centre d'Oncologie de Gentilly, Radiotherapy Department, 54 100 Nancy, France.
authors.forename: Pierre
authors.initials: P
authors.lastname: Baumann
authors.affiliation: Centre Henri Becquerel, Radiotherapy Department, 76038 Rouen, France.
authors.forename: Fernand
authors.initials: F
authors.lastname: Missohou
authors.affiliation: Centre François Baclesse, Radiotherapy Department, 14000 Caen, France.
authors.forename: Christelle
authors.initials: C
authors.lastname: Levy
authors.affiliation: Centre Georges-François Leclerc, Département de radiothérapie, 21000 Dijon, France.
authors.forename: Karine
authors.initials: K
authors.lastname: Peignaux
authors.affiliation: CHU Tours, Service de cancérologie, 37044 Tours, France.
authors.forename: Pierre
authors.initials: P
authors.lastname: Bougnoux
authors.affiliation: Centre Jean Bernard, Département de radiothérapie, 72000 Le Mans, France.
authors.forename: Fabrice
authors.initials: F
authors.lastname: Denis
authors.affiliation: Institut Curie, Hospital, Radiotherapy Department, 75005 Paris, France.
authors.forename: Marc
authors.initials: M
authors.lastname: Bollet
authors.affiliation: Institut Curie, Hospital, Radiotherapy Department, 75005 Paris, France.
authors.forename: Rémi
authors.initials: R
authors.lastname: Dendale
authors.affiliation: Roche, France.
authors.forename: Nora Ady
authors.initials: NA
authors.lastname: Vago
authors.affiliation: Institut Curie, Hospital, Radiotherapy Department, 75005 Paris, France.
authors.forename: François
authors.initials: F
authors.lastname: Campana
authors.affiliation: Institut Curie, Hospital, Radiotherapy Department, 75005 Paris, France.
authors.forename: Alain
authors.initials: A
authors.lastname: Fourquet
authors.affiliation: Institut Curie, Hospital, Radiotherapy Department, 75005 Paris, France. Electronic address: youlia.kirova@curie.fr.
authors.forename: Youlia M
authors.initials: YM
authors.lastname: Kirova
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000473:pathology / Q000628:therapy*; D018270:Carcinoma, Ductal, Breast / Q000473:pathology / Q000628:therapy*; D018275:Carcinoma, Lobular / Q000473:pathology / Q000628:therapy*; D059186:Chemoradiotherapy, Adjuvant / Q000009:adverse effects*; D003872:Dermatitis / Q000209:etiology; D004417:Dyspnea / Q000209:etiology; D004941:Esophagitis / Q000209:etiology; D005260:Female; D005355:Fibrosis; D006801:Humans; D008209:Lymphedema / Q000209:etiology; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D011446:Prospective Studies; D011832:Radiation Injuries / Q000209:etiology*; D011838:Radiation-Sensitizing Agents / Q000009:adverse effects; D012867:Skin / Q000473:pathology*; D013684:Telangiectasis / Q000209:etiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D011838:Radiation-Sensitizing Agents; D000068258:Bevacizumab
keywords: Breast cancer; Concurrent bevacizumab; Radiotherapy